Clinical Trial Update: Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the immunogenicity and safety of the Recombinant Zoster Vaccine in adults living with HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine) (recombinant zoster vaccine)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Vaccination; Infection, Vaccine Adverse Reaction | Phase 4 | Status: ACTIVE_NOT_RECRUITING